Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/09/cvbnbvnvhgdftgf.png)
**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors**
**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors**
![Monoclonal ADC](https://www.medtourcn.com/wp-content/uploads/2024/09/cvbnbvnvhgdftgf.png)
Monoclonal ADC
#MonoclonalADC #Nectin4 #Solidtumor #9MW2821 #cervicalcancer #urothelialcarcinoma #esophagealcancer #breastcancer
Meet 9MW2821, a groundbreaking monoclonal antibody-drug conjugate (ADC) developed in China that targets Nectin-4, an adhesion molecule highly expressed in several solid tumors, including cervical cancer (CC), urothelial carcinoma (UC), esophageal cancer (EC), and breast cancer. Recently, this innovative therapy was granted Breakthrough Therapy Designation by the China Center for Drug Evaluation (CDE) for treating locally advanced or metastatic urothelial carcinoma, specifically in patients who have previously failed platinum-based chemotherapy and PD-(L)1 inhibitors.
The latest clinical results were unveiled at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the remarkable efficacy of 9MW2821 in a Phase 1/2 trial involving 260 patients with various advanced solid tumors. These included UC, triple-negative breast cancer (TNBC), EC, and CC. Among 37 evaluable UC patients, the disease control rate (DCR) soared to an impressive 91.9%, with an objective response rate (ORR) of 62.2%. Additionally, the median overall survival (mOS) reached 14.2 months, while the median progression-free survival (mPFS) was 8.8 months.
This promising therapy is poised to redefine treatment paradigms for patients with advanced solid tumors who have limited options, marking a significant milestone in the global oncology landscape.
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/t8c/1/16/1f389.png)
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp:+8613717959070
Email: doctor.huang@globecancer.com
#OncologyBreakthrough #CancerTreatment #Nectin4 #ADC #ClinicalResearch #Immunotherapy #UC #TNBC #CancerAwareness #BiotechInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/09/微信截图_20240904115259.jpg)
China’s new drug Aumolertinib Mesilate Tablets: The world’s second EGFR-targeted therapy for lung cancer with gene mutations.
China’s new drug Aumolertinib Mesilate Tablets: The world’s second EGFR-targeted therapy for lung cancer with gene mutations.
![lung cancer](https://www.medtourcn.com/wp-content/uploads/2024/09/微信截图_20240904115259.jpg)
lung cancer
#LungCancer #EGFRInhibitor #TargetedTherapy #Aumolertinib #NSCLC
Aumolertinib Mesilate Tablets (Ameile) were approved for marketing in China on March 18, 2020. It is China’s first third-generation EGFR-targeted therapy for lung cancer with gene mutations and the second such drug globally, following Osimertinib.
On August 20, 2024, the new indication marketing application for Aumolertinib Mesilate Tablets was accepted for priority review by the China Center for Drug Evaluation (CDE). This indication is for the treatment of unresectable locally advanced non-small cell lung cancer (NSCLC) that has not progressed following platinum-based chemoradiotherapy. This is the fourth indication for which the drug has submitted a marketing application, and it is expected to be approved in the second quarter of 2025.
The Phase 1 clinical trial (NCT0298110) enrolled a total of 120 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The results showed an objective response rate (ORR) of 52% (range: 42–63), with a disease control rate (DCR) as high as 92% (range: 84–96). The median progression-free survival was 11.0 months (95% CI: 9.5-not reached).
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/t8c/1/16/1f389.png)
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #ClinicalTrials #PharmaInnovation #Oncology #DrugApproval #Biotech #PrecisionMedicine
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/09/9月2日英文字幕-封面.jpg)
China’s first BCMA CAR-T therapy successfully treats an overseas patient with advanced relapsed multiple myeloma
China’s first BCMA CAR-T therapy successfully treats an overseas patient with advanced relapsed myeloma.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp:+8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#MultipleMyeloma #CAR-T #CancerTreatment #MedicalBreakthrough #Oncology #HealthcareInnovation #BCMACART
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/cvbnchfgyjuf6rr5tyrydxfrfes1.png)
Multiple Myeloma Solution ** Breakthroughs and Hope in Blood Cancer Treatment**
Multiple Myeloma Solution
** Breakthroughs and Hope in Blood Cancer Treatment**
![Mutiple Myeloma](https://www.medtourcn.com/wp-content/uploads/2024/08/cvbnchfgyjuf6rr5tyrydxfrfes1.png)
Mutiple Myeloma
Multiple myeloma is a malignant blood cancer caused by the abnormal proliferation of plasma cells in the bone marrow, often affecting the bones, kidneys, and various organs and systems. With the advancement of modern medical technology, the understanding and treatment of multiple myeloma have greatly improved, bringing unprecedented hope to patients.
### Causes and Risk Factors of Multiple Myeloma
The causes of multiple myeloma are complex, typically involving multiple factors such as genetic mutations, immune system abnormalities, exposure to harmful chemicals, viral infections, and genetic predisposition. Additionally, lifestyle and environmental factors like smoking, obesity, and certain occupational exposures are also believed to increase the risk of developing the disease. With an aging population, the incidence of multiple myeloma is on the rise.
### Evolution of Treatment: Traditional and Innovative Approaches
Although multiple myeloma was once considered a difficult-to-treat disease, recent advancements in treatment methods have made significant progress. Traditional treatments include chemotherapy, radiation therapy, and bone marrow transplantation, which have extended patients’ survival to some extent but come with limited efficacy and significant side effects.
However, with advances in medical technology, new treatment options have emerged. Monoclonal antibodies have played a key role in treating multiple myeloma, targeting cancer cells precisely while reducing harm to healthy cells. Antibody-drug conjugates take this a step further by delivering chemotherapy drugs directly to cancer cells, enhancing efficacy while minimizing side effects.
Small molecule targeted drugs represent another breakthrough. These drugs inhibit specific genes or proteins in cancer cells, preventing their growth and spread. For example, BCL-2 inhibitors and protein kinase inhibitors have shown promising results in clinical trials, offering more treatment options.
### Immunotherapy: Leading the Future of Hope
Immunotherapy is becoming increasingly important in the treatment of blood cancers, especially in the field of multiple myeloma. By activating the patient’s own immune system to attack cancer cells, immunotherapy holds great promise. Among the most forward-looking therapies is CAR-T cell therapy. This treatment involves genetically modifying a patient’s T cells to recognize and kill cancer cells, and it has achieved remarkable results in multiple myeloma patients.
In recent years, China has made significant progress in the research and application of immunotherapy. Particularly in the field of blood cancers, China has developed a comprehensive treatment system with established protocols and consensus. The BCMA-targeted CAR-T cell therapy has shown deep and lasting efficacy in treating multiple myeloma, greatly improving patients’ disease-free survival rates. For instance, China’s fully human BCMA-targeted CAR-T product, Equecabtagene Autoleucel, has demonstrated the best data among CAR-T products for multiple myeloma, with a complete remission rate of 82.4%.
### Looking Ahead
With the continuous emergence of new drugs and therapies, the treatment of multiple myeloma is moving towards individualized and precision medicine. Patients not only experience extended lifespans but also regain their quality of life, returning to normalcy in their everyday lives and work. As medical advancements continue, there is reason to believe that multiple myeloma will no longer be an incurable disease, and every patient will be able to embrace a brighter future.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070 (Http://wa.me/+8613717959070)
Email: doctor.huang@globecancer.com
#BloodCancerTreatment #CAR_TCellTherapy #CancerBreakthrough #Immunotherapy #BCMACART #MedicalAdvancements #CancerSurvivorship #ChinaMedicalInnovation #HopeForCancerPatients
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240822154626.jpg)
Celebrating Discharge: The Joy of a New Life/ Hope /Multiple myeloma
Celebrating Discharge: The Joy of a New Life/ Hope /Multiple myeloma
After a period of treatment, the Singaporean patient Teresa achieved remarkable results with CAR-T therapy at Jiahui International Hospital in Shanghai. Her condition reached complete remission (CR), and to celebrate this great news, the hospital held a brief yet heartwarming celebration for her.
In the celebratory photos, Teresa, along with Dr. Vicky Lee and her team of doctors and nurses, are all smiles, radiating the joy of victory. The photos not only captured this happiness but also served as a testament to the hard work and professionalism of the medical staff. Every member of Dr. Vicky Lee’s team is a true hero, using their expertise and selfless dedication to help Teresa overcome her illness.
Teresa, filled with emotion, said: “Although the treatment process was tough, I felt immense warmth and support from the doctors and nurses at Jiahui Hospital. Their professionalism and care gave me confidence, which ultimately led to such a successful outcome.”
On the day of her discharge, the medical staff extended their heartfelt blessings to Teresa. The nurses kindly reminded her of the precautions she needed to take after leaving the hospital, ensuring she could maintain good health during her recovery at home. Teresa expressed her gratitude to each member of the medical team, thanking them for the care and support they provided when she needed it most.
Standing at the hospital entrance, Teresa looked back on her treatment journey, filled with gratitude and hope. She knew that it was because of the selfless dedication and outstanding professionalism of these medical professionals that she could embrace health once again and look forward to a new chapter in life.
Teresa’s recovery story is not only a personal victory but also the result of the collective efforts of the entire medical staff at Jiahui Hospital. She is deeply grateful for their hard work and believes that many more patients will find new hope for recovery here in the future.
We will continue to follow the patient’s post-treatment progress and provide updates.
#CART #CARTTherapy #Hopeforpatients #FUCASO #Equecel #MultipleMyeloma #jihuiHospital #Shanghai #ChineseCart #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART #cancerfight #cancersurvivor #Jiahuihospital
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240820152652.jpg)
Redefining Hope for High-Risk RRMM Patients Worldwide: A Singaporean Patient`s Journey to China for Groundbreaking CAR-T Therapy
Redefining Hope for High-Risk RRMM Patients Worldwide: A Singaporean Patient`s Journey to China for Groundbreaking CAR-T Therapy
![Multiple Myeloma](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240820152652.jpg)
Multiple Myeloma
#MultipleMyeloma #CAR_Therapy #CancerTreatment #HRMM #MM #RRMM #CART
In the fight against multiple myeloma (MM), the last few decades have seen significant advancements, yet the disease remains notoriously difficult to cure, particularly in patients with relapsed/refractory multiple myeloma (RRMM). These patients face enormous challenges, as their options become increasingly limited after multiple lines of therapy have failed. However, hope has emerged in the form of BCMA CAR-T therapy, offering deep remission and long-term survival for those who had nearly lost hope.
One such case is a 58-year-old woman from Singapore, who after exhausting all available treatments in her home country, found new hope in China`s innovative CAR-T therapy. Diagnosed with MM in May 2021 following a month of severe back pain, she underwent a series of treatments including CD38 monoclonal antibodies, immunomodulatory drugs (IMiDs), proteasome inhibitors (PI), and XPO-1 inhibitors. Unfortunately, these therapies failed to halt the progression of her disease, which had become highly resistant to treatment.
In December 2023, she traveled to Beijing Chaoyang Hospital, Capital Medical University, where Professor Chen Wenming took charge of her case. The patient was diagnosed with high-risk MM (IgG-κ type) and admitted to the hospital on November 25, 2023, for CAR-T therapy.
#### The Treatment Journey: A Detailed Overview
Given the patient’s refractory nature and multiple prior treatments, Professor Chen devised a tailored treatment plan to improve her chances of survival and quality of life. In November 2023, her lymphocytes were collected to prepare the CAR-T cells. During this period, she received two cycles of D-PACE (dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) chemotherapy in Singapore to control the extramedullary plasmacytoma.
In February 2024, she returned to Beijing for further evaluation, where her condition was assessed as showing minimal response (MR). She was then administered a lymphodepletion regimen of fludarabine and cyclophosphamide on February 29. The following month, she received a transfusion of BCMA CAR-T cells.
Within five days post-transfusion, the patient developed a fever, which peaked at 39°C. Fortunately, her oxygen saturation and heart rate remained normal, and she was diagnosed with Grade 1 cytokine release syndrome (CRS). After symptomatic treatment, her blood counts recovered by day 15, and she was discharged in stable condition.
Two weeks post-CAR-T therapy, her response was evaluated as a very good partial response (VGPR), and by the two-month mark, her condition had improved to complete remission (CR) with minimal residual disease (MRD) negativity.
#### Insights from Leading Experts
Professor Wee Joo Chng, a specialist in high-risk MM, noted the aggressive nature of the patient’s disease, marked by genetic abnormalities like 1q21+ and t(4;14). Despite the use of multiple potent therapies, including KRd, XVd, and Isa-Pd, the patient’s disease continued to progress rapidly. The emergence of the del(17p) mutation further complicated her prognosis, indicating the need for a novel therapeutic approach.
The FUMANBA-1 study has highlighted the effectiveness of China`s indigenous CAR-T product, Equecabtagene Autoleucel, in achieving deep remission and prolonging survival in RRMM patients. This case demonstrated the therapy`s potential to overcome poor prognostic factors and extend the patient’s survival. Notably, the patient experienced only mild CRS and no immune effector cell-associated neurotoxicity syndrome (ICANS) or infections during treatment. At the two-month follow-up, the patient’s condition had improved to CR with MRD negativity, suggesting that Equecabtagene Autoleucel could be a game-changer for high-risk RRMM patients.
#### A New Frontier in CAR-T Therapy
RRMM patients with double-hit characteristics often experience early relapse and progression, leading to shortened survival times. Traditional therapies, including IMiDs, PIs, and monoclonal antibodies, have failed to overcome these poor prognostic factors, indicating the urgent need for novel treatments. Real-world studies have shown that CAR-T therapy offers comparable progression-free survival (PFS) and overall survival (OS) rates in RRMM patients, regardless of high-risk cytogenetic abnormalities.
The FUMANBA-1 study revealed impressive outcomes for Equecabtagene Autoleucel in RRMM patients, with an overall response rate (ORR) of 98.9% and an MRD negativity rate of 97.8% among CAR-T-naive patients. The CR rate was 82.4%, and 81.7% of patients maintained MRD negativity for over a year.
Globally, four CAR-T products are currently available, and a recent study presented at the 2024 European Society for Blood and Marrow Transplantation (EBMT) compared the short- and long-term efficacy of these therapies. The study’s matching-adjusted indirect comparison (MAIC) analysis revealed that Equecabtagene Autoleucel had a 12-month PFS rate of 94.2%, higher than the 75% observed with Ciltacabtagene autoleucel (CARTITUDE-1 study). Furthermore, the 12-month sustained MRD negativity rate for Equecabtagene Autoleucel was 100%, compared to 53.1% for Ciltacabtagene autoleucel.
These findings suggest that Equecabtagene Autoleucel, a Chinese-developed BCMA CAR-T therapy, offers superior long-term efficacy compared to its U.S. counterpart. As the global community celebrates the first anniversary of its approval, Equecabtagene Autoleucel continues to bring hope to RRMM patients worldwide, further solidifying China’s leading role in the field of cellular therapy.
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/t8c/1/16/1f389.png)
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp:+8613717959070
Email: doctor.huang@globecancer.com
#ChinaMedicalInnovation #GlobalHealth #MMResearch #PatientCare #InnovativeMedicine #CellTherapy #MedicalBreakthrough
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240814134905.jpg)
**Chinese Biopharmaceuticals: Ushering in a New Era in Nasopharyngeal Carcinoma Treatment, EBV-Specific CAR-T Injection Approved for Phase II Clinical Trials in the US and China**
**Chinese Biopharmaceuticals: Ushering in a New Era in Nasopharyngeal Carcinoma Treatment, EBV-Specific CAR-T Injection Approved for Phase II Clinical Trials in the US and China**
![Nasopharyngeal Carcinoma](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240814134905.jpg)
Nasopharyngeal Carcinoma
#Nasopharyngeal #Carcinoma #BRG01 #CART #EBVspecific
Biosyngen has announced a milestone achievement: the company’s independently developed BRG01 injection (EBV-specific CAR-T) has received formal written approval from the U.S. Food and Drug Administration (FDA) to conduct pivotal Phase II clinical trials for the treatment of relapsed/metastatic EBV-positive nasopharyngeal carcinoma patients. This is the world’s first original cell drug for solid tumors approved in both the US and China to enter Phase II trials, bringing hope and breakthroughs to the field of solid tumor treatment.
Previously reported, the Center for Drug Evaluation (CDE) of the National Medical Products Administration has agreed to conduct pivotal Phase II clinical trials of BRG01 injection (EBV-specific CAR-T). Patients for the BRG01 US-China Phase I clinical trials completed enrollment by the end of January this year, and all trial participants have received BRG01 reinfusion treatment. The Phase I registered clinical trial of BRG01 has successfully completed DLT (dose-limiting toxicity) observation and efficacy evaluation in 9 patients, all of whom were advanced nasopharyngeal carcinoma patients who had failed at least one treatment, including PD-1 antibody immune checkpoint inhibitors.
The data shows that BRG01 has demonstrated excellent safety and preliminary efficacy: in PET-CT scans, 75% of high-dose patients experienced a local reduction in tumor lesions and a decrease in metabolic activity, with some patients achieving 100% complete remission of tumor lesions. Additionally, BRG01 also demonstrated excellent anti-EB virus efficacy, with a significant reduction of EB virus load in the peripheral blood of patients after reinfusion to normal levels.
These data not only highlight the potential of BRG01 in tumor treatment but also demonstrate its dual advantages in antiviral therapy, laying a solid foundation for future clinical applications. This is believed to be the key reason for the FDA’s approval of BRG01 to enter Phase II clinical trials.
The FDA’s approval not only highly recognizes the preliminary research results of BRG01 injection but also fully affirms Biosyngen’s innovative capabilities and research and development strength in the field of cellular immunotherapy. Biosyngen will take this as an opportunity to accelerate the clinical research process of BRG01 injection, striving to achieve the commercialization of this therapy as soon as possible to bring benefits to nasopharyngeal carcinoma patients worldwide.
Biosyngen’s layout in the field of solid tumor cell therapy goes far beyond this. The company has become a biotech enterprise with three major cellular therapies for both solid and hematological tumors: CAR-T, TCR-T, and TIL. The product pipelines have completed dual submissions and approvals in both the US and China, and the indications for the latter two include a variety of solid tumors such as lung and liver cancer.
Looking to the future, with Biosyngen’s efficient execution and rapid R&D achievements, we have reason to expect more clinical breakthroughs in solid tumor cell drugs in a shorter time, bringing new treatment hopes to patients.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#Biosyngen #CAR_T #CancerTreatment #NasopharyngealCarcinoma #FDAApproval #ClinicalTrials #MedicalBreakthrough #BiotechInnovation #CancerResearch #Immunotherapy #HealthcareInnovation #CancerHope #SolidTumors #GlobalHealth #CancerCare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240813100412.jpg)
**A Groundbreaking ADC Drug for Cervical Cancer Approved in China Macau**
**A Groundbreaking ADC Drug for Cervical Cancer Approved in China Macau**
![Cervical Cancer](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240813100412.jpg)
Cervical Cancer
On August 6, 2024, Zai Lab proudly announced the approval of TIVDAK® (tisotumab vedotin-tftv) in Macau, marking the world’s first ADC (antibody-drug conjugate) specifically for cervical cancer. This innovative treatment is intended for patients with recurrent or metastatic cervical cancer who have experienced disease progression during or after chemotherapy.
TIVDAK stands as a significant milestone, being the first ADC drug approved by the FDA for cervical cancer. Following its accelerated approval in 2021, the FDA granted full approval in April 2024, solidifying its use for patients needing treatment after chemotherapy failure.
The FDA’s full approval was backed by positive outcomes from the global Phase 3 clinical trial, innovaTV 301. This study demonstrated that patients treated with TIVDAK experienced an overall survival benefit compared to those receiving chemotherapy. This finding is particularly noteworthy, as TIVDAK is the first ADC drug globally to show clear survival benefits for patients with second and third-line metastatic or recurrent cervical cancer.
Cervical cancer remains a leading threat in women’s health. Despite advancements in prevention through vaccination and early diagnosis via screening, there remains a significant unmet need for effective treatments. In China alone, an estimated 150,000 new cases are diagnosed each year, with approximately 60,000 fatalities. At the time of diagnosis, around 15% of adult patients have metastatic disease. For those diagnosed early and receiving treatment, up to 61% experience recurrence.
Zai Lab is participating in the global innovaTV 301 study and anticipates submitting a marketing application in China by early 2025. This approval in Macau represents a significant step forward in providing new hope for cervical cancer patients worldwide.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#CervicalCancer #ADCDrug #TIVDAK #ZaiLab #CancerTreatment #WomenHealth #MedicalAdvancement #FDAApproval #ClinicalTrial #Macau #GlobalHealth #InnovativeTherapy #PatientCare #Pharmaceuticals
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240812145103.jpg)
Nature Communications | Chinese Medical Team Innovates CAR-T Therapy to Bring New Hope for AML Treatment
Nature Communications | Chinese Medical Team Innovates CAR-T Therapy to Bring New Hope for AML Treatment
![AML](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240812145103.jpg)
AML
In the field of hematological malignancies, the treatment of acute myeloid leukemia (AML) has long been a challenge in the medical community. Particularly for relapsed or refractory patients, the limitations of traditional treatments have increased the urgent need for new therapies. With the advancements in immunotherapy technology, the continuous updating of CAR-T cell therapy has brought new possibilities for the treatment of AML.
Recently, a study titled “CAR-T Cells with C-JUN Overexpression in Acute Myeloid Leukemia: Preclinical Features and Phase I Trial” was published in the journal Nature Communications. This study comprehensively explores the potential optimization mechanisms of CAR-T therapy in AML and was jointly completed by doctors and professors from three top hospitals in China.
During an interview, the Chinese medical team stated that in designing this study, they focused on the major obstacles in CAR-T cell therapy for AML. Although CD33, a highly expressed target, has been extensively explored in multiple studies, safety and efficacy remain challenges. The study found that high expression of CD155 affects the ERK signaling pathway, thereby hindering the effective expansion of CD33. To address this challenge, the research team ultimately selected the overexpression of C-JUN to enhance the exhaustion resistance of CAR-T cells by screening ERK pathway genes. Preliminary results from the clinical trial showed that this overexpressed CD33 CAR-T cell exhibited significant advantages in antitumor function.
Despite the progress, the challenges in CAR-T therapy for AML treatment were also emphasized, including the balance between high efficacy and low toxicity, the expansion of CAR-T cells in myeloid leukemia cells, and the affinity of antibody binding. Subsequent research will focus more on addressing these key issues to enable more patients to benefit from CAR-T therapy.
The Chinese clinical trials revealed some key findings of CAR-T therapy, such as the effectiveness of the bridging transplant strategy and the remarkable efficacy of CD33 CAR-T cells derived from transplant donors. These studies not only provide new insights into the application of CAR-T therapy in AML but also offer references for the optimization of therapies targeting other antigens.
The Chinese medical team will continue to conduct in-depth research around the three core issues of toxicity, expansion, and antigen binding, aiming to overcome challenges and enable more patients to benefit from the breakthrough results of CAR-T cell therapy.
����To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#CAR_TCellTherapy #AcuteMyeloidLeukemia #AMLResearch #ImmunotherapyAdvancements #ChineseMedicalInnovation #CancerTreatment #MedicalBreakthrough #NatureCommunications #OncologyResearch #HematologicalMalignancies
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240808175732.jpg)
Overcoming Challenges and Embracing New Life! – Breakthrough Progress of Eque-cel in the Treatment of Refractory Multiple Myeloma
### Overcoming Challenges and Embracing New Life! – Breakthrough Progress of Eque-cel in the Treatment of Refractory Multiple Myeloma
![Multiple Myeloma](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240808175732.jpg)
Multiple Myeloma
In the treatment of multiple myeloma (MM), how do we find new breakthroughs for patients who have not achieved complete remission (CR) after multiple rounds of chemotherapy? Research by Chinese medical professors has provided an exciting answer: Eque-cel (BCMA CAR-T therapy).
**Patient Background:**
This 58-year-old female patient was initially admitted to the hospital due to numbness and pain in both lower limbs and was eventually diagnosed with multiple myeloma. Despite receiving various treatment regimens, including VRD and SVPD, the results were unsatisfactory, and complete remission was not achieved. Faced with refractory characteristics, the doctors decided to try a more innovative treatment plan—CAR-T cell therapy.
**Treatment Process:**
In September 2023, the patient began peripheral blood mononuclear cell collection, followed by bridging therapy, and in November 2023, she received the Eque-cel infusion. Remarkably, just one month later, the patient achieved hematologic complete remission (CR) with minimal residual disease (MRD) negativity. After six months of follow-up, the patient maintained this excellent therapeutic effect.
**Professor’s Insights:**
Chinese medical professors pointed out that the advent of Eque-cel has brought new hope to refractory MM patients. The drug demonstrated significant efficacy in the FUMANBA-1 study: the overall response rate was as high as 98.9%, with 82.4% achieving complete remission, and 97.8% of patients achieving MRD negativity. The 12-month sustained MRD negativity rate reached 81.7%, and the PFS rate was 85.5%.
This outstanding result proves the significant advantage of Eque-cel in improving the depth of remission for MM patients, bringing hope for long-term survival to many refractory patients.
**Future Outlook:**
As the application and research of Eque-cel continue, we look forward to it providing better treatment options and survival opportunities for more MM patients. This new treatment plan is bringing a ray of hope to this stubborn disease and providing valuable experience for clinical experts worldwide.
**Stay Tuned:**
We will continue to follow the latest developments and research progress of Eque-cel, looking forward to its greater role globally, bringing hope and blessings to more patients.
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/t8c/1/16/1f389.png)
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp:+8613717959070
Email: doctor.huang@globecancer.com
#MultipleMyeloma #CARTTherapy #MedicalBreakthrough #EqueCel #CancerTreatment #MedicalResearch #Hematology #PatientCare #OncologyInnovation #HopeForPatients #BCMA #CART #MM #RRMM
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240801100213.jpg)
Blood Cancer Solution Including leukemia, lymphoma, multiple myeloma, and others.
Blood Cancer Solution![👍](https://static.xx.fbcdn.net/images/emoji.php/v9/tfc/1/16/1f44d.png)
Including leukemia, lymphoma, multiple myeloma, and others.
![Blood Cancer](https://www.medtourcn.com/wp-content/uploads/2024/08/微信截图_20240801100213.jpg)
Blood Cancer
#leukemia #lymphoma #multiplemyeloma
#Hematologic malignancies are a group of malignant diseases originating from hematopoietic cells, often affecting the bone marrow, blood, and various organs and tissues throughout the body. Common types of hematologic malignancies include leukemia, myelodysplastic syndromes, lymphomas, multiple myeloma, and myeloproliferative neoplasms.
The causes of these diseases are complex, involving genetic mutations, immune abnormalities, radiation exposure, contact with harmful chemicals, infections, and hereditary factors. Additionally, poor lifestyle habits, high levels of stress, and environmental factors can also increase the risk of developing these conditions.
With an aging population and advancements in medical technology, the incidence of hematologic malignancies has been rising globally. In China, the incidence and mortality rates of leukemia and lymphoma are now among the top ranks of all malignancies.
However, hematologic malignancies are not incurable. In recent years, the treatment methods for these diseases have seen significant progress. From traditional combination chemotherapy and radiotherapy to hematopoietic stem cell transplantation, monoclonal antibody therapy, antibody-drug conjugates, small molecule targeted therapies, and the latest immunotherapies, treatment options have become increasingly diverse and precise.
Combination chemotherapy remains a primary treatment for many hematologic malignancies, despite its significant side effects. The efficacy of these treatments cannot be ignored. Modern chemotherapy regimens are continually being refined, including the incorporation of new cytotoxic drugs and targeted therapies, as well as the use of monoclonal antibodies. Additionally, the appropriate use of antiemetics, hematopoietic growth factors, and anti-infective agents helps to mitigate adverse effects.
Hematopoietic stem cell transplantation continues to be one of the most effective treatments for certain hematologic malignancies. The development of this treatment in China has been rapid, with 170 registered transplant centers by 2020.
Monoclonal antibodies, often referred to as “biological missiles,” have a high degree of specificity and single biological activity. They have revolutionized the treatment of hematologic malignancies. Antibody-drug conjugates (ADCs) utilize monoclonal antibodies to accurately identify tumor cell markers, guiding the delivery of chemotherapy drugs for targeted treatment.
Small molecule targeted therapies work by interfering with specific genes or proteins to inhibit tumor cell growth and proliferation. Gleevec, the first small molecule targeted therapy, increased the five-year survival rate for chronic myeloid leukemia (CML) patients from 30% to 89%, marking a breakthrough in cancer treatment. Today, there are numerous small molecule targeted drugs available for the treatment of hematologic malignancies, including BCR-ABL inhibitors, BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, and XPO1 inhibitors, with many more drugs currently in clinical trials expected to become available soon.
Immunotherapy includes immune checkpoint inhibitors (such as PD-1/L1), cancer vaccines, cellular immunotherapies (such as #CART), and nonspecific immunomodulatory treatments. #CARTtherapy, in particular, has gained widespread attention as an emerging curative treatment. This approach involves extracting a patient’s T cells, modifying them outside the body to specifically recognize and attack tumor cells, and then reinfusing the modified T cells into the patient. This therapy has been successfully applied to various hematologic malignancies, including acute lymphoblastic leukemia, lymphomas, and multiple myeloma. The first patient treated with CAR-T therapy has been disease-free for 11 years.
In recent years, China has made significant advances in the treatment of hematologic malignancies. The establishment of the “Chinese Expert Consensus on the Diagnosis and Treatment of High-Risk Multiple Myeloma” and the presentation by Professor Huang He at the 2024 #EHA conference on targeting CD7 universal CAR-T therapy for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) have shown remarkable efficacy and safety. Additionally, exciting new data from the 2024 American Society of Clinical Oncology (#ASCO) annual meeting highlighted the efficacy of Relma-cel in treating relapsed/refractory large B-cell lymphoma (R/R LBCL), with a four-year overall survival rate (#OS) of 66.7%. Particularly noteworthy is the research on multiple myeloma, where the BCMA-targeted CAR-T therapy has demonstrated deep and lasting responses, with a complete response (#CR) rate of 82.4% and a 12-month progression-free survival (#PFS) rate of 85.5%.
With the continuous development of new treatments and the emergence of new drugs, hematologic malignancies in China are no longer considered incurable diseases. Through standardized, individualized, and precise treatments, many patients with hematologic malignancies can achieve long-term disease-free survival, and even a cure, returning to normal work and life. As medicine continues to advance, every life will continue to shine brightly!
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/t8c/1/16/1f389.png)
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com![👍](https://static.xx.fbcdn.net/images/emoji.php/v9/tfc/1/16/1f44d.png)
#HematologicMalignancies #LeukemiaAwareness #LymphomaResearch #MultipleMyeloma #BloodCancer #CancerResearch #CAR_Therapy #StemCellTransplant #Immunotherapy #TargetedTherapy #MonoclonalAntibodies #CancerTreatment #MedicalAdvancements #CancerSurvivor #HealthcareInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/07/副作用eng1.png)
Expert Perspective: Side Effects and Management of CAR-T Therapy for a Thai Patient